Compare GNS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | XLO |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 49.8M |
| IPO Year | 2021 | 2021 |
| Metric | GNS | XLO |
|---|---|---|
| Price | $0.23 | $8.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 14.3M | 22.6K |
| Earning Date | 03-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.20 | $0.46 |
| 52 Week High | $1.92 | $9.25 |
| Indicator | GNS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 61.52 |
| Support Level | $0.21 | $7.47 |
| Resistance Level | $0.48 | $8.97 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 26.93 | 95.63 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.